Phagenova Bio, Inc

PhageNova Bio, Inc., based in Scarsdale, NY, is at the forefront of pioneering targeted gene expression technology aimed at enhancing cancer therapy and vaccine development. The company has created a novel gene delivery vector that selectively targets tumor cells while minimizing toxicity to normal cells and tissues.

With a focus on solid tumors and COVID-19, PhageNova Bio is advancing its lead asset, PNB001, through critical preclinical and IND-enabling efforts, including pivotal toxicology studies and GMP manufacturing. The company has established broad intellectual property protections and has successfully raised significant funding to support its innovative research and development initiatives.

Generated from the website